AU2001261741A1 - Diagnosis, prevention and treatment of crohn's disease using the ompc antigen - Google Patents

Diagnosis, prevention and treatment of crohn's disease using the ompc antigen

Info

Publication number
AU2001261741A1
AU2001261741A1 AU2001261741A AU6174101A AU2001261741A1 AU 2001261741 A1 AU2001261741 A1 AU 2001261741A1 AU 2001261741 A AU2001261741 A AU 2001261741A AU 6174101 A AU6174101 A AU 6174101A AU 2001261741 A1 AU2001261741 A1 AU 2001261741A1
Authority
AU
Australia
Prior art keywords
disease
crohn
diagnosis
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261741A
Inventor
Jonathan Braun
Christopher L. Sutton
Stephan R Targan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
University of California
Original Assignee
Cedars Sinai Medical Center
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, University of California filed Critical Cedars Sinai Medical Center
Publication of AU2001261741A1 publication Critical patent/AU2001261741A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/395—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Saccharomyces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Abstract

The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
AU2001261741A 2000-05-19 2001-05-17 Diagnosis, prevention and treatment of crohn's disease using the ompc antigen Abandoned AU2001261741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/575,061 US7138237B1 (en) 2000-05-19 2000-05-19 Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US09575061 2000-05-19
PCT/US2001/016032 WO2001089361A2 (en) 2000-05-19 2001-05-17 Diagnosis, prevention and treatment of crohn's disease using the ompc antigen

Publications (1)

Publication Number Publication Date
AU2001261741A1 true AU2001261741A1 (en) 2001-12-03

Family

ID=24298769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261741A Abandoned AU2001261741A1 (en) 2000-05-19 2001-05-17 Diagnosis, prevention and treatment of crohn's disease using the ompc antigen

Country Status (8)

Country Link
US (4) US7138237B1 (en)
EP (1) EP1285271B1 (en)
JP (1) JP4917728B2 (en)
AT (1) ATE302411T1 (en)
AU (1) AU2001261741A1 (en)
DE (1) DE60112744T2 (en)
ES (1) ES2247115T3 (en)
WO (1) WO2001089361A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
DK1581119T3 (en) 2001-12-17 2013-05-13 Corixa Corp Compositions and Methods for Therapy and Diagnosis of Inflammatory Bowel Diseases
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20040076960A1 (en) * 2002-10-18 2004-04-22 Taylor Kent D. Methods of using a NOD2/CARD15 haplotype to diagnose Crohn's disease
US7018188B2 (en) 2003-04-08 2006-03-28 The Procter & Gamble Company Apparatus for forming fibers
WO2004091372A2 (en) * 2003-04-11 2004-10-28 Cedars-Sinai Medical Center Methods of assessing crohn’s disease patient phenotype by i2, ompc and asca serologic response
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
FR2876798A1 (en) * 2004-10-14 2006-04-21 Univ Clermont Auvergne DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP2270512B1 (en) * 2004-12-08 2016-03-23 Cedars-Sinai Medical Center Methods for diagnosis of Crohn's disease
JP4577083B2 (en) * 2005-04-28 2010-11-10 味の素株式会社 How to diagnose Crohn's disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20070282714A1 (en) * 2006-04-27 2007-12-06 Snocap, Inc. System, method and computer program product for providing an e-commerce interface on a web page to facilitate e-commerce involving digital assets
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
EP2359137A4 (en) 2008-11-11 2012-05-30 Prometheus Lab Inc Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
JP5660027B2 (en) * 2009-03-05 2015-01-28 味の素株式会社 Crohn's disease diagnostic reagent
ES2553415T3 (en) 2009-04-14 2015-12-09 Nestec S.A. Prognosis method of inflammatory bowel disease
JP5736370B2 (en) 2009-06-25 2015-06-17 ネステク ソシエテ アノニム Diagnosis of irritable bowel syndrome
MX339330B (en) 2009-08-14 2016-05-20 Procter & Gamble Spinning die assembly and method for forming fibres using said assembly.
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
US8445215B1 (en) 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
CN103502815B (en) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 Detect the determination method for the autoantibody of anti-TNF alpha medicine
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
BR112013028808A2 (en) 2011-05-10 2016-09-06 Nestec Sa Disease Activity Profile Characterization Methods for Personalized Therapy Management
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
MX352274B (en) 2011-10-21 2017-11-16 Nestec Sa Methods for improving inflammatory bowel disease diagnosis.
MX358730B (en) 2012-10-05 2018-09-03 Nestec Sa Methods for predicting and monitoring mucosal healing.
KR20210157418A (en) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
AU2016349703A1 (en) * 2015-11-06 2018-11-01 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5681699A (en) 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US5932429A (en) * 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

Also Published As

Publication number Publication date
EP1285271B1 (en) 2005-08-17
EP1285271A2 (en) 2003-02-26
US20090221007A1 (en) 2009-09-03
US7138237B1 (en) 2006-11-21
JP4917728B2 (en) 2012-04-18
WO2001089361A2 (en) 2001-11-29
US20070161065A1 (en) 2007-07-12
EP1285271A4 (en) 2003-07-23
ES2247115T3 (en) 2006-03-01
US7993865B2 (en) 2011-08-09
DE60112744T2 (en) 2006-06-14
ATE302411T1 (en) 2005-09-15
WO2001089361A3 (en) 2002-03-28
DE60112744D1 (en) 2005-09-22
US7993866B2 (en) 2011-08-09
US7993867B2 (en) 2011-08-09
JP2004526122A (en) 2004-08-26
US20090221006A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn's disease using the ompc antigen
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
HK1015413A1 (en) Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharaceutical compositions
WO2003011899A3 (en) Antigenic polypeptides
WO2002058717A3 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
WO2000033872A3 (en) Method of and compositions for immunization with the pseudomonas v antigen
WO2004069873A3 (en) Antigen/antibody or ligand/receptor glycosylated specificity exchangers
WO2002064161A3 (en) Method and compositions for immunization with the pseudomonas v antigen
EP1354896A4 (en) Novel monoclonal antibody
AU4396401A (en) Composition and method for the prevention and/or the treatment of allergy
MX237690B (en) System and method of verifying the authenticity of dynamically connectable executable images.
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
EP1028754A4 (en) Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
ITRM940297A0 (en) "DEVICE FOR THE TRANSMISSION OF MANUAL ACCELERATION, BRAKING AND SIMILAR COMMANDS".
WO2001068134A3 (en) Therapies that improve graft survival, using antibodies against a b7 antigen
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
AU7128098A (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
AU3637195A (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
NZ514691A (en) Method to type prion proteins